159 related articles for article (PubMed ID: 16232017)
1. Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder.
Van Brunt DL; Johnston JA; Ye W; Pohl GM; Sun PJ; Sterling KL; Davis ME
Pharmacotherapy; 2005 Nov; 25(11):1541-9. PubMed ID: 16232017
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
3. Decreased use of clonidine following treatment with atomoxetine in children with ADHD.
Johnston JA; Ye W; Van Brunt DL; Pohl G; Sumner CR
J Clin Psychopharmacol; 2006 Aug; 26(4):389-95. PubMed ID: 16855457
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy with atomoxetine for US children and adolescents.
Bhatara VS; Aparasu RR
Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019
[TBL] [Abstract][Full Text] [Related]
5. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
[TBL] [Abstract][Full Text] [Related]
6. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
[TBL] [Abstract][Full Text] [Related]
8. Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.
Gerhard T; Winterstein AG; Olfson M; Huang C; Saidi A; Crystal S
Pharmacoepidemiol Drug Saf; 2010 May; 19(5):457-64. PubMed ID: 20232490
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
10. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
Marcus SC; Wan GJ; Kemner JE; Olfson M
Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
12. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data.
Van Brunt DL; Johnston JA; Ye W; Pohl GM; O'Hara NN
J Manag Care Pharm; 2006 Apr; 12(3):230-8. PubMed ID: 16623607
[TBL] [Abstract][Full Text] [Related]
14. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
15. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
16. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
Biederman J; Gao H; Rogers AK; Spencer TJ
Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
[TBL] [Abstract][Full Text] [Related]
17. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003.
Sankaranarayanan J; Puumala SE; Kratochvil CJ
Curr Med Res Opin; 2006 Aug; 22(8):1475-91. PubMed ID: 16870073
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
Polzer J; Bangs ME; Zhang S; Dellva MA; Tauscher-Wisniewski S; Acharya N; Watson SB; Allen AJ; Wilens TE
Biol Psychiatry; 2007 Mar; 61(5):713-9. PubMed ID: 16996485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
